Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer
Authors
Keywords
-
Journal
ONCOGENE
Volume 42, Issue 20, Pages 1620-1633
Publisher
Springer Science and Business Media LLC
Online
2023-04-05
DOI
10.1038/s41388-023-02676-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
- (2022) Alissa J. Cooper et al. Nature Reviews Clinical Oncology
- Loss of MIG-6 results in endometrial progesterone resistance via ERBB2
- (2022) Jung-Yoon Yoo et al. Nature Communications
- EGFR Inhibition Potentiates FGFR Inhibitor Therapy and Overcomes Resistance in FGFR2 Fusion–Positive Cholangiocarcinoma
- (2022) Qibiao Wu et al. Cancer Discovery
- Targeting RAS mutant colorectal cancer with dual inhibition of MEK and CDK4/6
- (2022) Alexey V. Sorokin et al. CANCER RESEARCH
- KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
- (2022) Meagan B. Ryan et al. Cell Reports
- Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
- (2022) Jill Hallin et al. NATURE MEDICINE
- The current state of the art and future trends in RAS-targeted cancer therapies
- (2022) Salman R. Punekar et al. Nature Reviews Clinical Oncology
- Combining neratinib with CDK4/6, mTOR and MEK inhibitors in models of HER2-positive cancer
- (2021) Ming Zhao et al. CLINICAL CANCER RESEARCH
- BCL6 confers KRAS-mutant non–small-cell lung cancer resistance to BET inhibitors
- (2021) Jiawei Guo et al. JOURNAL OF CLINICAL INVESTIGATION
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Precision oncology in metastatic colorectal cancer — from biology to medicine
- (2021) Federica Di Nicolantonio et al. Nature Reviews Clinical Oncology
- The origins and genetic interactions of KRAS mutations are allele- and tissue-specific
- (2021) Joshua H. Cook et al. Nature Communications
- A Review of the Diagnosis and Treatment of Metastatic Colorectal Cancer
- (2021) Jeffrey Bien et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- EGFR activation limits the response of liver cancer to lenvatinib
- (2021) Haojie Jin et al. NATURE
- Sotorasib for Lung Cancers with KRAS p.G12C Mutation
- (2021) Ferdinandos Skoulidis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Acquired Resistance to KRASG12C Inhibition in Cancer
- (2021) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Apoptosis-inducing activity of synthetic hydrocarbon-stapled peptides in H358 cancer cells expressing KRASG12C
- (2021) Cuicui Li et al. Acta Pharmaceutica Sinica B
- Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor
- (2021) Xiaolun Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Sotorasib for previously treated colorectal cancers with KRASG12C mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial
- (2021) Marwan G Fakih et al. LANCET ONCOLOGY
- Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
- (2020) E. Martinelli et al. ANNALS OF ONCOLOGY
- Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition
- (2020) Jenny Y. Xue et al. NATURE
- Relationships Between Immune Landscapes, Genetic Subtypes and Responses to Immunotherapy in Colorectal Cancer
- (2020) Emilie Picard et al. Frontiers in Immunology
- The Frequency of Ras Mutations in Cancer
- (2020) Ian A. Prior et al. CANCER RESEARCH
- EGFR blockade reverts resistance to KRAS G12C inhibition in colorectal cancer
- (2020) Vito Amodio et al. Cancer Discovery
- Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling
- (2020) Huai-Xiang Hao et al. CLINICAL CANCER RESEARCH
- Therapeutics Targeting Mutant KRAS
- (2020) Kyaw Z. Thein et al. Annual Review of Medicine
- Immunotherapy of colorectal cancer: Challenges for therapeutic efficacy
- (2019) Davide Ciardiello et al. CANCER TREATMENT REVIEWS
- Global burden of colorectal cancer: emerging trends, risk factors and prevention strategies
- (2019) NaNa Keum et al. Nature Reviews Gastroenterology & Hepatology
- Patient-Derived Organoids Predict Chemoradiation Responses of Locally Advanced Rectal Cancer
- (2019) Ye Yao et al. Cell Stem Cell
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
- (2018) Rona Yaeger et al. CANCER CELL
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E -Mutant Colorectal Cancer
- (2018) Ryan B. Corcoran et al. Cancer Discovery
- KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition
- (2018) Sandra Misale et al. CLINICAL CANCER RESEARCH
- OncogenicKrasdrives invasion and maintains metastases in colorectal cancer
- (2017) Adam T. Boutin et al. GENES & DEVELOPMENT
- The long noncoding RNA lnc-EGFR stimulates T-regulatory cells differentiation thus promoting hepatocellular carcinoma immune evasion
- (2017) Runqiu Jiang et al. Nature Communications
- Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells
- (2017) Chun Xie et al. Frontiers in Pharmacology
- The induction of MIG6 under hypoxic conditions is critical for dormancy in primary cultured lung cancer cells with activating EGFR mutations
- (2016) H Endo et al. ONCOGENE
- Colorectal Cancer Heterogeneity and Targeted Therapy: A Case for Molecular Disease Subtypes
- (2015) J. F. Linnekamp et al. CANCER RESEARCH
- Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer
- (2015) Scott Kopetz et al. JOURNAL OF CLINICAL ONCOLOGY
- Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma
- (2015) T. K. Maity et al. Cancer Discovery
- Colorectal cancer
- (2015) Ernst J. Kuipers et al. Nature Reviews Disease Primers
- Wentilactone B induces G2/M phase arrest and apoptosis via the Ras/Raf/MAPK signaling pathway in human hepatoma SMMC-7721 cells
- (2013) Z Zhang et al. Cell Death & Disease
- Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
- (2012) Anirudh Prahallad et al. NATURE
- EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
- (2012) Ryan B. Corcoran et al. Cancer Discovery
- Oncogenic and Wild-type Ras Play Divergent Roles in the Regulation of Mitogen-Activated Protein Kinase Signaling
- (2012) Amy Young et al. Cancer Discovery
- A two-tiered mechanism of EGFR inhibition by RALT/MIG6 via kinase suppression and receptor degradation
- (2010) Yuri Frosi et al. JOURNAL OF CELL BIOLOGY
- Negative Regulation of the EGFR-MAPK Cascade by Actin-MAL-Mediated Mig6/Errfi-1 Induction
- (2009) Arnaud Descot et al. MOLECULAR CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search